Ba/F3 Xenograft Model Services

Next-Generation Kinase Inhibitor Screening

Standardized head-to-head comparisons to identify lead candidates with superior specificity.

• Broad spectrum coverage – Leveraging a library of 400+ engineered cell lines covering BCR-ABL, EML4-ALK, RET, FGFR, and other common/rare targets.
• Efficacy benchmarking – Comparative assessment of novel chemical entities against first-and second-generation inhibitors to establish competitive advantage.

Resistance Mechanism & Escape Profiling

Engineered to simulate clinically relevant acquired resistance, as validated in recent FLT3 mutation studies.

• Mechanism analysis – Deep signaling profiling (p-STAT5, p-AKT, p-ERK) to demonstrate how agents such as Gilteritinib overcome mutations that bypass earlier‑generation inhibitors (e.g., Quizartinib).
• Rare mutation targeting – Custom engineering for AKT1/2-E17K and other challenging nodes to validate next-generation inhibitors.

Biologics & Combination Regimen Evaluation

Optimized for complex biologics (ADCs, bispecifics) in addition to small molecules.

• Combination synergism – Using EGFR Exon 19 insertion and L858R/C797S models to evaluate the synergistic therapeutic window of dual-targeting molecules (e.g., ZNL-0056) in combination with standard-of-care TKIs.